GWAS study of myelosuppression among NSCLC patients receiving platinum-based combination chemotherapy

• A genome-wide association study identified rs6856089 and linked SNPs as significantly associated with platinum-based chemotherapy-induced myelosuppression in NSCLC patients. • Patients carrying the A allele of rs6856089 had a markedly lower risk of myelosuppression (OR = 0.1300, P = 7.59 × 10–8). • Gene-based analysis implicated EMCN, encoding endomucin, a hematopoietic stem cell marker, as a potential mediator of myelosuppression. • These findings provide a scientific basis for personalized therapeutic approaches to reduce myelosuppression in NSCLC patients receiving platinum-based chemotherapy.